Diffuse midline glioma treated with epigenetic agent-based immunotherapy
Open Access
- 20 January 2023
- journal article
- letter
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experienceJournal of Neuro-Oncology, 2022
- Hallmarks of Cancer: New DimensionsCancer Discovery, 2022
- Leptomeningeal disease in glioblastoma: endgame or opportunity?Journal of Neuro-Oncology, 2021
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisNature Medicine, 2020
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomasNature Medicine, 2017